NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
NervGen Pharma Corp. - Common stock (NGEN)
Company Research
Source: GlobeNewswire
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced the Company will present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium, which is being held February 15-17, 2026, in Washington, DC. Details of the presentation are as follows: Title:Emerging Therapies with Challenges and Opportunities for the FutureFormat:Presentation and Panel DiscussionDate/Time: Sunday, February 15th, 2026, 4:15-5:00 pm ETPresenter:Adam Rogers, MD, President
Show less
Read more
Impact Snapshot
Event Time:
NGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGEN alerts
High impacting NervGen Pharma Corp. - Common stock news events
Weekly update
A roundup of the hottest topics
NGEN
News
- NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical AffairsGlobeNewswire
- NervGen Pharma to Participate at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- NervGen Pharma to Participate at Upcoming Investor ConferencesGlobeNewswire
- NervGen Pharma Announces Retirement of Chief Financial Officer, Bill AdamsGlobeNewswire
- NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium [Yahoo! Finance]Yahoo! Finance
NGEN
Sec Filings
- 2/13/26 - Form 6-K
- 2/10/26 - Form 6-K
- 1/23/26 - Form S-8
- NGEN's page on the SEC website